{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T17:40:50Z","timestamp":1789926050619,"version":"4.0.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bradykinin-mediated angioedema comprises rare but potentially life-threatening disorders, most notably hereditary angioedema (HAE) due to C1 inhibitor (C1-INH) deficiency or dysfunction. Diagnosis is often difficult, as these conditions can resemble urticaria variants, leading to misdiagnosis and delays in care. Distinguishing features are critical, since bradykinin-mediated forms do not respond to antihistamines or corticosteroids. This review summarizes the differential diagnoses of angioedema, including urticaria variants, cheilitis granulomatosa, and hypocomplementemic urticarial vasculitis, highlighting clinical and diagnostic clues. Particular focus is given to HAE\u2014its subtypes (Type I, Type II, and normal C1-INH), pathophysiology, presentation, and genetic basis. Acquired angioedema and drug-induced forms, such as ACE inhibitor\u2013associated angioedema, are also discussed. The therapeutic landscape is rapidly evolving, spanning acute and prophylactic approaches. Options include C1-INH concentrate, kallikrein inhibitors, bradykinin receptor antagonists, and factor XII inhibitors. While these advances expand treatment opportunities, they also complicate decision-making for patients and physicians. Furthermore, emerging CRISPR-based gene editing therapies represent innovative approaches that pose complex ethical dilemmas, and their long-term safety and efficacy have yet to be established. Although novel therapies reduce attack frequency, their true impact on quality of life is not fully established. Comparative effectiveness data are limited, long-term safety\u2014particularly of gene-based therapies\u2014is unknown, and the real-world utility of new oral on-demand agents for acute therapy is uncertain, especially in severe pharyngeal or laryngeal attacks that may hinder swallowing. Current guidelines remain unclear on the need for short-term prophylaxis in patients already receiving effective long-term prophylactic therapy. In conclusion, despite major therapeutic advances, persistent challenges and unanswered questions underscore the need for pragmatic, patient-centered, long-term studies to optimize care.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1681763","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:49:34Z","timestamp":1759297774000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Unraveling angioedema: diagnostic challenges and emerging therapies"],"prefix":"10.3389","volume":"16","author":[{"given":"Felix","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Hofauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2020.602016\/BIBTEX","article-title":"Stimulation of vibratory urticaria-associated adhesion-GPCR, EMR2\/ADGRE2, triggers the NLRP3 inflammasome activation signal in human monocytes","volume":"11","author":"I","year":"2020","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1016\/J.JID.2020.03.936","article-title":"Critical signaling events in the mechanoactivation of human mast cells via P.C492y-adgre2","volume":"140","author":"Naranjo","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.01.028","article-title":"Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials","volume":"154","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/J.JACI.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/J.JACI.2023.10.007","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","volume":"153","author":"Jain","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2408792\/SUPPL_FILE\/NEJMOA2408792_DATA-SHARING.PDF","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"AB366","DOI":"10.1016\/j.jaci.2023.11.873","article-title":"Barzolvolimab significantly decreases chronic spontaneous urticaria disease activity and is well tolerated: top line results from a phase 2 trial","volume":"153","author":"Maurer","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/S40265-025-02170-4","article-title":"Update on the treatment of chronic spontaneous urticaria","volume":"85","author":"Kolkhir","year":"2025","journal-title":"Drugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.12968\/HMED.2022.0416\/ASSET\/IMAGES\/LARGE\/HMED.2022.0416_T03.JPEG","article-title":"Management of orofacial granulomatosis","volume":"29","author":"Joshi","year":"2023","journal-title":"Br J Hosp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.7759\/CUREUS.57723","article-title":"Unraveling the diagnosis of hypocomplementemic urticarial vasculitis syndrome","volume":"16","author":"Bukhari","year":"2024","journal-title":"Cureus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/J.JACI.2022.02.007\/ASSET\/00674F99-F32A-454A-9A48-5E1688F1E8E6\/MAIN.ASSETS\/GR4.JPG","article-title":"Urticarial vasculitis: Clinical and laboratory findings with a particular emphasis on differential diagnosis","volume":"149","author":"Marzano","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMRA2400092","article-title":"Cryoglobulinemia \u2014 One name for two diseases","volume":"391","author":"Cacoub","year":"2024","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/BIOM14060646","article-title":"Schnitzler syndrome: insights into its pathogenesis, clinical manifestations, and current management","volume":"14","author":"Braud","year":"2024","journal-title":"Biomolecules"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.08.046","article-title":"US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema","volume":"9","author":"Busse","year":"2020","journal-title":"The Journal of Allergy and Clinical Immunology: In Practice ScienceDirectJourna"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1007\/S12016-021-08897-8","article-title":"The mortality from hereditary angioedema worldwide: a review of the real-world data literature","volume":"62","author":"Minafra","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/PAI.14268","article-title":"Hereditary angioedema in children: Review and practical perspective for clinical management","volume":"35","author":"Pagnier","year":"2024","journal-title":"Pediatr Allergy Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/S40629-018-0088-5\/METRICS","article-title":"Guideline: Hereditary angioedema due to C1 inhibitor deficiency","volume":"28","author":"Bork","year":"2019","journal-title":"Allergo J Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.15214","article-title":"The international WAO\/EAACI guideline for the management of hereditary angioedema\u2014The 2021 revision and update","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/FPHYS.2023.1146834","article-title":"Mechanisms involved in hereditary angioedema with normal C1-inhibitor activity","volume":"14","author":"Shamanaev","year":"2023","journal-title":"Front Physiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.jaip.2017.09.025","article-title":"Hereditary angioedema with normal C1 inhibitor and F12 mutations in 42 Brazilian families","volume":"6","author":"Veronez","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/FGENE.2019.00900","article-title":"Bradykinin-mediated angioedema: An update of the genetic causes and the impact of genomics","volume":"10","author":"Marcelino-Rodriguez","year":"2019","journal-title":"Front Genet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/J.JAIP.2024.12.027","article-title":"Angioedema due to acquired C1-inhibitor deficiency without hematological condition: A multicenter french cohort study of 34 patients","volume":"13","author":"Stammler","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/S13023-023-02625-5","article-title":"C1-inhibitor\/C1-inhibitor antibody complexes in acquired angioedema due to C1-inhibitor deficiency","volume":"18","author":"Polai","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/S10072-021-05279-Y","article-title":"Related factors with orolingual angioedema after intravenous alteplase in acute ischemic stroke: results from a single-center cohort and meta-analysis","volume":"43","author":"Mas-Serrano","year":"2022","journal-title":"Neurol Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.26355\/EURREV_201803_14496","article-title":"Analysis of related factors of orolingual angioedema after rt-PA intravenous thrombolytic therapy","volume":"22","author":"Wang","year":"2018","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2017.02.018","article-title":"Epidemiology of ACE inhibitor angioedema utilizing a large electronic health record","volume":"5","author":"Banerji","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0230632","article-title":"Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports","volume":"15","author":"Dubrall","year":"2020","journal-title":"PLoS One"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1111\/CEA.14206","article-title":"The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema","volume":"52","author":"Maurer","year":"2022","journal-title":"Clin Exp Allergy"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13023-024-03251-5\/TABLES\/2","article-title":"Androgen transition and management of hereditary angioedema long-term prophylaxis in real life: a single-center case series","volume":"19","author":"Hoarau","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/FMED.2022.930403","article-title":"Pregnancy in women with Hereditary Angioedema due to C1-inhibitor deficiency: Results from the ITACA cohort study on outcome of mothers and children with in utero exposure to plasma-derived C1-inhibitor","volume":"9","author":"Triggianese","year":"2022","journal-title":"Front Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.02.043","article-title":"Clinical characteristics and safety of plasma-derived C1-inhibitor therapy in children and adolescents with hereditary angioedema\u2014A long-term survey","volume":"8","author":"Farkas","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA0805538","article-title":"Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema","volume":"363","author":"Zuraw","year":"2010","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13223-019-0362-1\/TABLES\/3","article-title":"Subcutaneous C1 inhibitor for prevention of attacks of hereditary angioedema: Additional outcomes and subgroup analysis of a placebo-controlled randomized study","volume":"15","author":"Li","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.14416","article-title":"Lanadelumab demonstrates rapid and sustained prevention of hereditary angioedema attacks","volume":"75","author":"Riedl","year":"2020","journal-title":"Allergy"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2018.16773","article-title":"Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: A randomized clinical trial","volume":"320","author":"Banerji","year":"2018","journal-title":"JAMA"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.15011","article-title":"Long-term prevention of hereditary angioedema attacks with lanadelumab: The HELP OLE Study","volume":"77","author":"Banerji","year":"2022","journal-title":"Allergy"},{"key":"B38","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/J.JAIP.2024.12.008","article-title":"Real-world effectiveness of lanadelumab in hereditary angioedema: multicountry INTEGRATED observational study","volume":"13","author":"Magerl","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00350-1","article-title":"Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Craig","year":"2023","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/ALL.16351","article-title":"Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study","volume":"80","author":"Reshef","year":"2025","journal-title":"Allergy Eur J Allergy Clin Immunol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/J.JAIP.2023.12.019","article-title":"Once-daily oral berotralstat for long-term prophylaxis of hereditary angioedema: the open-label extension of the APeX-2 randomized trial","volume":"12","author":"Kiani-Alikhan","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B42","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/J.JACI.2020.10.015","article-title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial","volume":"148","author":"Zuraw","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/S12016-023-08972-2\/FIGURES\/7","article-title":"A retrospective analysis of long-term prophylaxis with berotralstat in patients with hereditary angioedema and acquired C1-inhibitor deficiency\u2014Real-world data","volume":"65","author":"Johnson","year":"2023","journal-title":"Clin Rev Allergy Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANAI.2025.07.012","article-title":"Oral berotralstat for hereditary angioedema prophylaxis in patients aged 2 to <12 years: APeX-P interim results","author":"Bernatoniene","year":"2025","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMOA2314192\/SUPPL_FILE\/NEJMOA2314192_DATA-SHARING.PDF","article-title":"Oral sebetralstat for on-demand treatment of hereditary angioedema attacks","volume":"391","author":"Riedl","year":"2024","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2024.01.027","article-title":"Hereditary angioedema with normal C1-inhibitor: Clinical and genetic characterization of 15 Portuguese unrelated families","volume":"132","author":"Dias de Castro","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/S12016-025-09027-4","article-title":"Hereditary angioedema with normal C1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment","volume":"68","author":"Zuraw","year":"2025","journal-title":"Clin Rev Allergy Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/S10875-018-0553-4","article-title":"Treatment of hereditary angioedema attacks with icatibant and recombinant C1 inhibitor during pregnancy","volume":"38","author":"Hakl","year":"2018","journal-title":"J Clin Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1159\/000531074","article-title":"How does pregnancy and type of delivery affect the clinical course of hereditary angioedema","volume":"184","author":"Eyice Karabacak","year":"2023","journal-title":"Int Arch Allergy Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1159\/000512933","article-title":"Acquired angioedema with C1 inhibitor deficiency: occurrence, clinical features, and management: A nationwide retrospective study in the Czech Republic patients","volume":"182","author":"Sobotkova","year":"2021","journal-title":"Int Arch Allergy Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.10.017","article-title":"Efficacy and safety of rituximab-based treatments in angioedema with acquired C1-inhibitor deficiency","volume":"12","author":"Kalmi","year":"2024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B52","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13023-019-1043-3","article-title":"Angioedema due to acquired C1-inhibitor deficiency: spectrum and treatment with C1-inhibitor concentrate","volume":"14","author":"Bork","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.09.003","article-title":"Acquired angioedema due to C1-inhibitor deficiency (AAE-C1-INH)-A bicenter retrospective study on diagnosis, course, and therapy","volume":"14","author":"Trainotti","year":"","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/FIMMU.2024.1405317","article-title":"The real life experience goes on: update after 4 years on the first cohort treated with lanadelumab at our center","volume":"15","author":"Buttgereit","year":"2024","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA1312524\/SUPPL_FILE\/NEJMOA1312524_DISCLOSURES.PDF","article-title":"A randomized trial of icatibant in ACE-inhibitor\u2013induced angioedema","volume":"372","author":"Ba\u015f","year":"2015","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1056\/NEJMoa2402478","article-title":"Efficacy and safety of donidalorsen for hereditary angioedema","volume":"391","author":"Riedl","year":"2024","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.anai.2024.08.133","article-title":"Long-term treatment of hereditary angioedema attacks with oral deucrictibant: rapide-2 extension study results","volume":"133","author":"Anderson","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1016\/j.anai.2023.08.122","article-title":"Deucrictibant immediate-release capsule reduces time to end of progression of hereditary angioedema attacks\u2019 Manifestations","volume":"131","author":"Riedl","year":"2023","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/J.ANAI.2024.08.130","article-title":"Chapter-1 phase 2 trial of oral bradykinin B2 receptor antagonist deucrictibant for hereditary angioedema prophylaxis","volume":"133","author":"Wedner","year":"2024","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.001740","article-title":"STAR-0215 is a novel, long-acting monoclonal antibody inhibitor of plasma kallikrein for the potential treatment of hereditary angioedema","volume":"387","author":"Bedian","year":"2023","journal-title":"J Pharmacol Exp Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"AB196","DOI":"10.1016\/j.jaci.2024.12.611","article-title":"Treatment with navenibart (STAR-0215) reduces attack severity and use of rescue medication in patients with hereditary angioedema (HAE): interim results from the ALPHA-STAR trial","volume":"155","author":"Jacobs","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2309149","article-title":"CRISPR-Cas9 in vivo gene editing of KLKB1 for hereditary angioedema","volume":"390","author":"Longhurst","year":"2024","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/J.ANAI.2024.08.048","article-title":"Results from A phase 2, randomized, placebo-controlled trial of crispr-based therapy Ntla-2002 for hereditary angioedema","volume":"133","author":"Cohn","year":"2024","journal-title":"Ann Allergy Asthma Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1681763\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T05:49:35Z","timestamp":1759297775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1681763\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,1]]},"references-count":63,"alternative-id":["10.3389\/fimmu.2025.1681763"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1681763","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,1]]},"article-number":"1681763"}}